• CEO interview: Growth Strategy of Shionogi

What's New

  • Show All
2019/09/06
Shionogi to Announce Personnel Reassignment
2019/09/02
Positive Results for XOFLUZATM Global Phase III Study (MINISTONE-2) in Children with Influenza
2019/09/02
Shionogi Announces Positive Post-Exposure Prophylaxis Results for XOFLUZA® in Phase III Study (BLOCKSTONE) of Influenza Virus Infection in Household Members
2019/09/02
Special Drug Use Survey for XOFLUZA® Announced at OPTIONS X - Analysis of Rate of Appearance and Clinical Course of Mutated Viruses at Position 38 in PA Protein for Influenza A/H1N1pdm and A/H3N2 Presented-
2019/09/02
The Results of Analyses of PA/I38X-substituted Viruses in XOFLUZA® Clinical Studies
2019/08/29
Shionogi Announces XOFLUZA® Tablets 20mg for The Treatment of Influenza Types A and B in Patients 12 years of Age and older Approved in Taiwan.
2019/08/27
Shionogi to Participate in the United Nations Global Compact
2019/07/29
Financial Results for the First Quarter of FY2019
2019/07/22
Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa
2019/07/19
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
2019/06/24
Shionogi Concludes Licensing Agreements with Eddingpharm and EOC Pharma for Lusutrombopag, a Thrombopoietin Receptor Agonist and Epertinib, an HER2/EGFR Inhibitor
2019/06/19
SHIONOGI AND FERRER CONCLUDE A CONTRACT FOR THE PROMOTION IN SPAIN OF RIZMOIC® (NALDEMEDINE), A THERAPEUTIC AGENT FOR OPIOID-INDUCED CONSTIPATION
2019/06/18
Announcement about the Adjustment of the Conversion Value for Euro-Yen Denominated Convertible Bonds Maturing in 2019